Teva Pharmaceutical Industries annual current ratio
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Current Ratio Growth & History (TEVA)
Teva Pharmaceutical Industries's current ratio was 1.04 for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.04 | 0.06 | +5.66% |
| 2024 | 2024-12-31 | 0.98 | −0.04 | −3.78% |
| 2023 | 2023-12-31 | 1.02 | −0.03 | −2.98% |
| 2022 | 2022-12-31 | 1.05 | −0.09 | −7.85% |
| 2021 | 2021-12-31 | 1.14 | 0.15 | +15.41% |
| 2020 | 2020-12-31 | 0.99 | 0.00 | +0.33% |
| 2019 | 2019-12-31 | 0.98 | 0.02 | +2.23% |
| 2018 | 2018-12-31 | 0.96 | 0.10 | +12.21% |
| 2017 | 2017-12-31 | 0.86 | −0.07 | −7.89% |
| 2016 | 2016-12-31 | 0.93 | — | — |
| 2013 | 2013-12-31 | 1.15 | −0.12 | −9.64% |
| 2012 | 2012-12-31 | 1.27 | 0.21 | +20.08% |
| 2011 | 2011-12-31 | 1.06 | −0.19 | −14.92% |
| 2010 | 2010-12-31 | 1.24 | −0.36 | −22.61% |
| 2009 | 2009-12-31 | 1.61 | 0.26 | +19.13% |
| 2008 | 2008-12-31 | 1.35 | — | — |
Teva Pharmaceutical Industries quarterly current ratio
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
As of Dec 31, 2014
As of Mar 31, 2015
As of Jun 30, 2015
As of Sep 30, 2015
As of Dec 31, 2015
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.88 | −0.18 | −17.34% |
| Q1 2026 | 2026-03-31 | 1.01 | −0.02 | −1.95% |
| Q4 2025 | 2025-12-31 | 1.04 | 0.06 | +5.66% |
| Q3 2025 | 2025-09-30 | 1.11 | 0.22 | +24.18% |
| Q2 2025 | 2025-06-30 | 1.06 | 0.17 | +19.25% |
| Q1 2025 | 2025-03-31 | 1.03 | 0.14 | +15.89% |
| Q4 2024 | 2024-12-31 | 0.98 | −0.04 | −3.78% |
| Q3 2024 | 2024-09-30 | 0.89 | −0.11 | −10.99% |
| Q2 2024 | 2024-06-30 | 0.89 | −0.13 | −12.59% |
| Q1 2024 | 2024-03-31 | 0.89 | −0.21 | −19.29% |
| Q4 2023 | 2023-12-31 | 1.02 | −0.03 | −2.98% |
| Q3 2023 | 2023-09-30 | 1.00 | 0.01 | +0.98% |
| Q2 2023 | 2023-06-30 | 1.02 | −0.09 | −7.73% |
| Q1 2023 | 2023-03-31 | 1.10 | 0.03 | +3.03% |
| Q4 2022 | 2022-12-31 | 1.05 | −0.09 | −7.85% |
| Q3 2022 | 2022-09-30 | 0.99 | −0.03 | −3.39% |
| Q2 2022 | 2022-06-30 | 1.11 | 0.10 | +9.49% |
| Q1 2022 | 2022-03-31 | 1.07 | 0.05 | +4.52% |
| Q4 2021 | 2021-12-31 | 1.14 | 0.15 | +15.41% |
| Q3 2021 | 2021-09-30 | 1.03 | 0.02 | +2.30% |
| Q2 2021 | 2021-06-30 | 1.01 | −0.08 | −7.11% |
| Q1 2021 | 2021-03-31 | 1.03 | −0.02 | −1.89% |
| Q4 2020 | 2020-12-31 | 0.99 | 0.00 | +0.33% |
| Q3 2020 | 2020-09-30 | 1.00 | 0.12 | +13.01% |
| Q2 2020 | 2020-06-30 | 1.09 | 0.13 | +13.86% |
| Q1 2020 | 2020-03-31 | 1.05 | 0.09 | +9.21% |
| Q4 2019 | 2019-12-31 | 0.98 | 0.02 | +2.23% |
| Q3 2019 | 2019-09-30 | 0.89 | −0.05 | −5.02% |
| Q2 2019 | 2019-06-30 | 0.96 | −0.08 | −7.70% |
| Q1 2019 | 2019-03-31 | 0.96 | −0.04 | −3.81% |
| Q4 2018 | 2018-12-31 | 0.96 | 0.10 | +12.21% |
| Q3 2018 | 2018-09-30 | 0.94 | −0.02 | −2.26% |
| Q2 2018 | 2018-06-30 | 1.03 | 0.09 | +9.60% |
| Q1 2018 | 2018-03-31 | 1.00 | 0.06 | +6.70% |
| Q4 2017 | 2017-12-31 | 0.86 | −0.07 | −7.89% |
| Q3 2017 | 2017-09-30 | 0.96 | 0.06 | +6.23% |
| Q2 2017 | 2017-06-30 | 0.94 | −0.33 | −25.82% |
| Q1 2017 | 2017-03-31 | 0.93 | −0.38 | −29.16% |
| Q4 2016 | 2016-12-31 | 0.93 | −0.48 | −34.13% |
| Q3 2016 | 2016-09-30 | 0.90 | −0.06 | −6.40% |
| Q2 2016 | 2016-06-30 | 1.27 | 0.35 | +38.53% |
| Q1 2016 | 2016-03-31 | 1.32 | 0.06 | +4.50% |
| As of Dec 31, 2015 | 2015-12-31 | 1.41 | 0.24 | +20.76% |
| As of Sep 30, 2015 | 2015-09-30 | 0.96 | −0.23 | −19.27% |
| As of Jun 30, 2015 | 2015-06-30 | 0.92 | −0.22 | −19.59% |
| As of Mar 31, 2015 | 2015-03-31 | 1.26 | 0.08 | +6.85% |
| As of Dec 31, 2014 | 2014-12-31 | 1.17 | 0.02 | +2.16% |
| Q3 2014 | 2014-09-30 | 1.19 | 0.05 | +4.33% |
| Q2 2014 | 2014-06-30 | 1.14 | 0.04 | +4.09% |
| Q1 2014 | 2014-03-31 | 1.18 | 0.01 | +1.09% |
| Q4 2013 | 2013-12-31 | 1.15 | −0.12 | −9.64% |
| Q3 2013 | 2013-09-30 | 1.14 | −0.27 | −18.90% |
| Q2 2013 | 2013-06-30 | 1.10 | −0.32 | −22.78% |
| Q1 2013 | 2013-03-31 | 1.17 | 0.07 | +6.23% |
| Q4 2012 | 2012-12-31 | 1.27 | 0.21 | +20.08% |
| Q3 2012 | 2012-09-30 | 1.41 | 0.28 | +24.36% |
| Q2 2012 | 2012-06-30 | 1.42 | 0.17 | +13.38% |
| Q1 2012 | 2012-03-31 | 1.10 | −0.26 | −19.03% |
| Q4 2011 | 2011-12-31 | 1.06 | −0.19 | −14.92% |
| Q3 2011 | 2011-09-30 | 1.13 | −0.14 | −10.85% |
| Q2 2011 | 2011-06-30 | 1.25 | −0.51 | −28.96% |
| Q1 2011 | 2011-03-31 | 1.36 | −0.16 | −10.26% |
| Q4 2010 | 2010-12-31 | 1.24 | −0.36 | −22.61% |
| Q3 2010 | 2010-09-30 | 1.27 | −0.31 | −19.70% |
| Q2 2010 | 2010-06-30 | 1.77 | 0.24 | +15.81% |
| Q1 2010 | 2010-03-31 | 1.51 | 0.21 | +16.28% |
| Q4 2009 | 2009-12-31 | 1.61 | 0.26 | +19.13% |
| Q3 2009 | 2009-09-30 | 1.58 | — | — |
| Q2 2009 | 2009-06-30 | 1.52 | — | — |
| Q1 2009 | 2009-03-31 | 1.30 | — | — |
| Q4 2008 | 2008-12-31 | 1.35 | — | — |
Teva Pharmaceutical Industries current ratio trends
Over the last five fiscal years, Teva Pharmaceutical Industries's current ratio increased from 0.99 to 1.04, a change of 0.05. The latest reported quarter, Q2 2026, shows 0.88.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗